Education
About Us
Working with TipRanks
Follow Us
Repligen (RGEN)
:RGEN
RGEN Stock Chart & Stats
Day’s Range― - ―
52-Week Range$113.50 - $187.25
Previous CloseN/A
Volume111.19K
Average Volume (3M)742.20K
Market Cap
$7.70B
Enterprise Value$8.22B
Total Cash (Recent Filing)$0.00
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.22
Next Earnings
Apr 30, 2025EPS Estimate
0.35Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.46
Shares Outstanding56,148,556
10 Day Avg. Volume645,788
30 Day Avg. Volume742,203
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)12.52
Price to Cash Flow (P/CF)50.20
P/FCF Ratio50.20
Enterprise Value/Market Cap1.07
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit25.74
Enterprise Value/Ebitda81.13
Forecast
1Y Price Target
$189.27Price Target Upside38.03% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering15
---
Repligen News
See All RGEN News
---
Bulls Say, Bears Say
Bulls Say
Financial PerformanceThe company is expected to experience margin recovery with more than 200 basis points per year improvement.
Market GrowthRepligen is anticipated to grow significantly above the market due to differentiated products and a higher clinical mix.
Strategic AcquisitionRepligen's acquisition of 908 Devices' bioprocessing desktop assets is expected to enhance its capabilities in the bioprocessing sector.
Bears Say
Macroeconomic SensitivityRepligen's recovery process could face challenges due to sensitivity to a volatile macro environment.
Operational ChallengesRepligen's margins have experienced significant volatility due to a lull in demand, which should recover over the coming years.
Valuation ConcernsThe current demanding valuation is seen as difficult to justify, leading to a preference to wait for greater macro certainty.
---
Ownership Overview
0.72% Insiders
37.70% Mutual Funds
27.56% Other Institutional Investors
12.83% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
RGEN FAQ
What was Repligen’s price range in the past 12 months?
Repligen lowest stock price was $113.50 and its highest was $187.25 in the past 12 months.
What is Repligen’s market cap?
Repligen’s market cap is $7.70B.
When is Repligen’s upcoming earnings report date?
Repligen’s upcoming earnings report date is Apr 30, 2025 which is in 32 days.
How were Repligen’s earnings last quarter?
Repligen released its earnings results on Feb 20, 2025. The company reported $0.44 earnings per share for the quarter, beating the consensus estimate of $0.41 by $0.03.
Is Repligen overvalued?
According to Wall Street analysts Repligen’s price is currently Undervalued.
Does Repligen pay dividends?
Repligen does not currently pay dividends.
What is Repligen’s EPS estimate?
Repligen’s EPS estimate is 0.35.
How many shares outstanding does Repligen have?
Repligen has 56,148,556 shares outstanding.
What happened to Repligen’s price movement after its last earnings report?
Repligen reported an EPS of $0.44 in its last earnings report, beating expectations of $0.41. Following the earnings report the stock price went up 7.921%.
Which hedge fund is a major shareholder of Repligen?
Currently, no hedge funds are holding shares in RGEN
---
Repligen Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$189.27 (38.03% Upside)
$189.27 (38.03% Upside)
Blogger Sentiment
Neutral
RGEN Sentiment 50%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 130.4K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $4.0M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 3.1%
Last 30 Days ▼ 9.1%
Last 30 Days ▼ 9.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-25.78%
12-Months-Change
Fundamentals
Return on Equity
-1.30%
Trailing 12-Months
Asset Growth
-0.05%
Trailing 12-Months
Company Description
Repligen
Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. It also offers ELISA test kits; and chromatography resins under the CaptivA brand. In addition, the company provides filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and SpectraFlo dynamic dialysis systems; and ProConnex single-use hollow fiber. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has collaboration agreements with Navigo Proteins GmbH to develop multiple affinity ligands. Repligen Corporation was incorporated in 1981 and is headquartered in Waltham, Massachusetts.
---
RGEN Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
Repligen's earnings call highlighted strong growth in the CDMO and equipment segments, successful execution of strategic priorities, and positive outlook for 2025. However, challenges in China and the protein segment, along with restructuring charges, were notable lowlights. Despite these challenges, the positive aspects, including strong revenue growth and strategic achievements, outweigh the negatives.Read More>---
RGEN Revenue Breakdown
44.00% North America
37.00% Europe
19.00% APAC/Other
---
RGEN Stock 12 Month Forecast
Average Price Target
$189.27
▲(38.03% Upside)
Technical Analysis
Best Analysts Covering RGEN
1 Year
1 Year Success Rate
11/21 ratings generated profit
1 Year Average Return
+20.23%
reiterated a buy rating last month
Copying Daniel Arias's trades and holding each position for 1 Year would result in 52.38% of your transactions generating a profit, with an average return of +20.23% per trade.
---